Materials and methods for the treatment of celiac disease

Details Materials and methods for the treatment of celiac disease Materials and methods for the treatment of celiac disease

2007-10-26

2011-10-11

Raghu, Ganapathirama (Department: 1652)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S328000, C530S300000, C424S185100

Reexamination Certificate

active

08034776

ABSTRACT:
The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.

REFERENCES:
patent: 5827534 (1998-10-01), Fasano
patent: 5864014 (1999-01-01), Fasano
patent: 5912323 (1999-06-01), Fasano
patent: 5945510 (1999-08-01), Fasano
patent: 5948629 (1999-09-01), Fasano
patent: 6458925 (2002-10-01), Fasano
patent: 6670448 (2003-12-01), Fasano
patent: 6733762 (2004-05-01), Fasano et al.
patent: 6793936 (2004-09-01), Devane et al.
patent: 6936689 (2005-08-01), Fasano
patent: 7026294 (2006-04-01), Fasano et al.
patent: 7189696 (2007-03-01), Fasano
patent: 7294689 (2007-11-01), Fasano et al.
patent: 7531504 (2009-05-01), Fasano
patent: 7531512 (2009-05-01), Fasano et al.
patent: 7582603 (2009-09-01), Fasano
patent: 2003/0180352 (2003-09-01), Patel et al.
patent: 2006/0269968 (2006-11-01), Fasano
patent: 2009/0069247 (2009-03-01), Paterson et al.
patent: 0 557 897 (1993-09-01), None
patent: 0 675 199 (1995-10-01), None
patent: WO9837096 (1998-08-01), None
patent: WO9852415 (1998-11-01), None
patent: WO 00/07609 (2000-02-01), None
patent: WO0189551 (2001-11-01), None
patent: WO2004004696 (2004-01-01), None
International Search Report issued in PCT/US07/82720 on Aug. 1, 2008, 8 pages.
Fasano, “Biological Perspectives: Physiological, Pathological, and Therapeutic Implications of Zonulin-Mediated Intestinal Barrier Modulation—Living Life on the Edge of the Wall”, The American Journal of Pathology, Nov. 2008, vol. 173, No. 5, pp. 1243-1252.
Pizzuti et al., “Transcriptional downregulation of tight junction protein ZO-1 in active coeliac diseas is reversed after a gluten-free diet”, Digestive and Liver Disease, May 2004, vol. 36(5), pp. 337-341.
Fasano et al., “The Role of the Intestinal Barrier Function in the Pathogenesis of Celiac Disease—Frontiers in Celiac Disease”. Pediatric Adolescent Medicine Basel, Karger, 2008, vol. 12, pp. 89-98.
Fasano, “Surprises from Celiac Disease”, Scientific American, Aug. 2009, vol. 301(2), pp. 54-61.
Clayburgh et al., “A porous defense: the leaky epithelial barrier in intestinal disease”, Laboratory Investigation, 2004, vol. 84, pp. 282-291.
Wang et al., “Human zonulin, a potential modulator of intestinal tight junctions”, Journal of Cell Science, 2000, vol. 113, pp. 4435-4440.
Holmes et al., “Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns”, Gene Expression Patterns, 2006, vol. 6, pp. 581-588.
Murray, “The widening spectrum of celiac disease”, Am. J. Clin. Nutr., 1999, vol. 69, pp. 354-365.
Chiarioni et al., “Gluten-Free Diet Normalizes Mouth-to-Cecum Transit of a Caloric Meal in Adult Patients with Celiac Disease”, Digestive Diseases and Sciences, Oct. 1997, vol. 42, No. 10, pp. 2100-2105.
Deli, “Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery”, Biochemica et Biophysica Acta, 2009, 1788, pp. 892-910.
Fasano et al., “Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease”, The Lancet, Apr. 2000, vol. 355, pp. 1518-1519.
Ewe et al., “Inflammation Does Not Decrease Intraluminal pH in Chronic Inflammatory Bowel Disease”, Digestive Diseases and Sciences, Jul. 1999, vol. 44, No. 7, pp. 1434-1439.
Sadik et al., “Gut Transit in Celiac Disease: Delay of Small Bowel Transit and Acceleration after Dietary Treatment”, American Journal of Gastroenterology, Dec. 2004, vol. 99, No. 12, pp. 2429-2436.
McConnell et al., “Gut instincts: Explorations in intestinal physiology and drug delivery”, International Journal of Pharmaceutics, Dec. 2008, vol. 364, No. 2, pp. 213-226.
Sapone et al., “Zonulin Upregulation Is Associated With Increased Gut Permeability in Subjects With Type 1 Diabetes and Their Relatives”, Diabetes, May 2006, vol. 55, pp. 1443-1449.
Watts et al., “Role of the intestinal tight junction modulator zonulin in the pathogenesis of type 1 diabetes in BB diabetic-prone rates”, PNAS, Feb. 2005, vol. 102, No. 8, pp. 2916-2921.
Di Sabatino et al., “Coeliac Disease”, The Lancet, Apr. 2009, vol. 373, pp. 1480-1493.
Fasano et al., “Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases”, Nature Clinical Practice Gastroenterology & Hepatology, Sep. 2005, vol. 2, No. 9, pp. 416-422.
Arhewoh et al., “Optimising oral systems for the delivery of therapeutic proteins and peptides”, African Journal of Biotechnology, Dec. 2005, vol. 4(13), pp. 1591-1597.
Ciccocioppo et al., “Altered Expression, Localization, and Phosphorylation of Epithelial Junction Proteins in Celiac Disease”, American Journal of Clinical Pathology, 2006, vol. 125, pp. 502-511.
Drago et al., Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines, Scand.J.Gastroenterol.,2006, vol. 41:408-419.
Clemente et al., “Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function”, Gut, 2003, vol. 52, pp. 218-223.
Teahon et al., “Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease”, Gut, 1996, vol. 38, pp. 864-869.
Baudry et al., “Cloning of a Gene (zot) Encoding a New Toxin Produced byVibrio cholerae”, Infection and Immunity, Feb. 1992, vol. 60, No. 2., pp. 428-434.
Bolton et al., “Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo”, 1998, Neuroscience, vol. 86, No. 4, pp. 1245-1257.

Affiliated with

Also associated with

Rating

Materials and methods for the treatment of celiac disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Materials and methods for the treatment of celiac disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for the treatment of celiac disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4267525